TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02244632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modufolin (arfolitixorin)
Description: IV injection every second week for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modufolin (arfolitixorin)
Description: IV injection every second week for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modufolin (arfolitixorin)
Description: IV injection every second week for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modufolin (arfolitixorin)
Description: IV injection every second week for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modufolin (arfolitixorin)
Description: IV injection every second week for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modufolin (arfolitixorin)
Description: IV injection every second week for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: IV injection every second week for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: IV injection every second week for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: IV injection every second week for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: IV injection every second week for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: IV injection every second week for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: IV injection every second week for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: IV infusion every second week for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: IV infusion every second week for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: IV infusion every second week for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: IV infusion every second week for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: IV infusion every second week for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV infusion every second week for 8 weeks.
Study: NCT03865823

Intervention type: PROCEDURE
Intervention: pus sample
Description: A pus sample from the fistula will be taken by the doctor during this first consultation or, failing that, in the operating room before disinfection.
Study: NCT01764841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin DPI (BAYQ3939)
Description: Participants received 32.5 mg ciprofloxacin hydrated (corresponding to 50 mg dry powder) administered BID (every 12 hours) using T-326 powder inhaler device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin DPI (BAYQ3939)
Description: Participants received 32.5 mg ciprofloxacin hydrated (corresponding to 50 mg dry powder) administered BID (every 12 hours) using T-326 powder inhaler device.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours) using T-326 powder inhaler device.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours) using T-326 powder inhaler device.
Study: NCT02016326

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD Colon
Description: High Definition White Light

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-scan 1
Description: I-Scan 1 has Contrast Enhancement(CE), Surface Enhancement(SE). SE mode highlights light-dark contrast thereby providing more mucosal surface detail. CE mode digitally adds blue to darker areas providing detailed imaging of subtle mucosal irregularities.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-Scan 2
Description: I-Scan 1 has Contrast Enhancement(CE), Surface Enhancement(SE)and Tone Enhancement(TE). SE mode highlights light-dark contrast thereby providing more mucosal surface detail. CE mode digitally adds blue to darker areas providing detailed imaging of subtle mucosal irregularities. TE provides a uniform color image and is intended for detailed inspection of distinct lesions.
Study: NCT00797758

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cord blood transplantation
Description: Umbilical cord blood transplantation after reduced intensity conditioning
Study: NCT01528371

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: 1. Investigators select subject from patients for whom the doctor has ordered intravenous sedation. Inclusion criteria is SBP\>=140mmHg or DBP\>=90mmHg measuring when the patient sits on dental chair and has settled down for 5 minutes. Informed consent is obtained from the patient.~2. Patient conducts Japanese version of STAI and VAS about anxiety to dental treatment.~3. Investigators take venous line on the upper limb and inject the drug (midazolam at dose of 0.02mg/kg) intravenously. Investigators measure blood pressure, heart rate, and oxygen saturation every 2 minutes until 10 minutes after drug administration.~4. 10 minutes later, patient conducts Japanese version of STAI and VAS about anxiety to dental procedure again.~5. Investigators inject an additional sedative agent and the dental treatment is started.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Solution (NSS)
Description: 1. Investigators select subject from patients for whom the doctor has ordered intravenous sedation. Inclusion criteria is SBP\>=140mmHg or DBP\>=90mmHg measuring when the patient sits on dental chair and has settled down for 5 minutes. Informed consent is obtained from the patient.~2. Patient conducts Japanese version of STAI and VAS about anxiety to dental treatment.~3. Investigators take venous line on the upper limb and inject the drug (saline solution at dose of 0.004ml/kg) intravenously. Investigators measure blood pressure, heart rate, and oxygen saturation every 2 minutes until 10 minutes after drug administration.~4. 10 minutes later, patient conducts Japanese version of STAI and VAS about anxiety to dental procedure again.~5. Investigators inject an additional sedative agent and the dental treatment is started.
Study: NCT03040726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netupitant
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron Hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03962361

Intervention type: OTHER
Intervention: Concentration of circulating microparticles.
Description: The microparticles contained in the blood sample will be isolated by ultracentrifugation and quantified by flow cytometry. The microparticles concentration will be determined by the number of microparticles per uL of plasma, based on the volume of the sample, the flow rate of the cytometer and the number of fluorescent events.
Study: NCT02475369

Intervention type: DRUG
Group type: OTHER
Intervention: pancrelipase

Intervention type: DRUG
Group type: OTHER
Intervention: pancrelipase
Study: NCT01092767

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Valiant Thoracic Stent Graft with the Captivia Delivery System
Description: All subjects will be implanted with this device
Study: NCT02243657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3652
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3652
Description: oral
Study: NCT04301531

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Determination of Hb
Description: Hb of all children in the subgroup study are measured using a haemocure photometer.

Intervention type: OTHER
Group type: OTHER
Intervention: Determination of Hb
Description: Hb of all children in the subgroup study are measured using a haemocure photometer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Household survey
Description: Determine the prevalence of febrile illnesses among children in the subgroup study

Intervention type: OTHER
Group type: OTHER
Intervention: Household survey
Description: Determine the prevalence of febrile illnesses among children in the subgroup study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community-base management of malaria
Description: Between interventions, participant who become febrile are tested and treated if confirmed positive for malaria by CHWs

Intervention type: OTHER
Group type: OTHER
Intervention: Community-base management of malaria
Description: Between interventions, participant who become febrile are tested and treated if confirmed positive for malaria by CHWs
Study: NCT00239551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prevacid
Description: Effect of Prevacid on prostaglandin levels at 8 weeks; EGD (esophagogastroduodenal endoscopy) with biopsy at day 1 \& EGD with biopsy at 8 weeks
Study: NCT04836403

Intervention type: OTHER
Intervention: Sinus and nasal quality of life survey questionnaire (SN-5)
Description: The SN-5 consists of five questions on a 7-point scale that assesses the frequency of the following symptoms: (1) nasal obstruction, (2) sinus infection, (3) allergies, (4) emotional distress, and (5) activity limitations. The scoring system is as follows: 1 indicates none of the time, 2 indicating hardly any time at all, 3 indicates a small part of the time, 4 indicates some of the time, 5 indicates a good part of the time, 6 indicates most of the time, and 7 indicates all of the time. Higher scores indicate more severe sinonasal symptoms. One item from a global faces scale scored from 0 to 10 is used to evaluate overall QoL related to nasal or sinus disease. Higher scores on this scale indicate a less severe impact of nasal or sinus disease. The scores from the first five items (1-7 each)

Intervention type: OTHER
Intervention: Sinus and nasal quality of life survey questionnaire (SN-5)
Description: The SN-5 consists of five questions on a 7-point scale that assesses the frequency of the following symptoms: (1) nasal obstruction, (2) sinus infection, (3) allergies, (4) emotional distress, and (5) activity limitations. The scoring system is as follows: 1 indicates none of the time, 2 indicating hardly any time at all, 3 indicates a small part of the time, 4 indicates some of the time, 5 indicates a good part of the time, 6 indicates most of the time, and 7 indicates all of the time. Higher scores indicate more severe sinonasal symptoms. One item from a global faces scale scored from 0 to 10 is used to evaluate overall QoL related to nasal or sinus disease. Higher scores on this scale indicate a less severe impact of nasal or sinus disease. The scores from the first five items (1-7 each)

Intervention type: OTHER
Intervention: Sinus and nasal quality of life survey questionnaire (SN-5)
Description: The SN-5 consists of five questions on a 7-point scale that assesses the frequency of the following symptoms: (1) nasal obstruction, (2) sinus infection, (3) allergies, (4) emotional distress, and (5) activity limitations. The scoring system is as follows: 1 indicates none of the time, 2 indicating hardly any time at all, 3 indicates a small part of the time, 4 indicates some of the time, 5 indicates a good part of the time, 6 indicates most of the time, and 7 indicates all of the time. Higher scores indicate more severe sinonasal symptoms. One item from a global faces scale scored from 0 to 10 is used to evaluate overall QoL related to nasal or sinus disease. Higher scores on this scale indicate a less severe impact of nasal or sinus disease. The scores from the first five items (1-7 each)
Study: NCT03023761

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: low level laser
Description: low level laser irradiation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: laser sham
Description: laser without irradiation
Study: NCT00322543

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Corio™ Pimecrolimus-eluting stent
Study: NCT02951689

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Study: NCT02243657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3652
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3652
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3652
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study: NCT02938663

Intervention type: BEHAVIORAL
Intervention: Questionnaires and Measurements
Description: Participants completed anthropometric measurements and questionnaires assessing psychosocial stress, habitual dietary intake and physical activity as well as cultural identity, identity-based motivation and socioeconomic status. At home, participants recorded their habitual physical activity and food intake. Participants then returned to the laboratory to complete an assessment of identity-based motivation and received personalized information regarding their habitual physical activity and dietary patterns.
Study: NCT01242982

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Closed reduction and fixation with 2 pins
Description: Closed reduction and fixation with 2 antegrade intramedullary Kirschner wires. Cast for 2 weeks. Control after 2 and 5 weeks. Thereafter a control after 3,6 and 12 months

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reduction and Plaster of Paris
Description: Closed reduction in local anesthesia and a Plaster of Paris for max. 3 weeks. Control after 1 and 3 weeks, thereafter control after 3,6 and 12 months
Study: NCT00909467

Intervention type: OTHER
Intervention: echocardiography, right heart catheterisation
Description: at each patient an echocardiography will be performed at rest and during exercise. For the evaluation of exercise capacity, cardiopulmonary exercise testing and six-minute walk is performed. Right heart catheterisation is recommended to those with suspected pulmonary hypertension.
Study: NCT04773132

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Protein
Description: Low protein/protein-free diet for 3 days (Day 1, 2 and Day 3) in order to deplete the label protein pool. The diet provided will meet the daily energy requirements of all the subjects.
Study: NCT01865019

Intervention type: DEVICE
Intervention: mechanical ventilation

Intervention type: DEVICE
Intervention: mechanical ventilation
Study: NCT03462680

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: niacin
Description: Niacin or nicotinic acid 250 mg tablets

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablet
Study: NCT01470534

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: carbohydrate drink
Description: carbohydrate drink

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: carbohydrate drink
Description: carbohydrate drink

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Muscle biopsy
Description: Open muscle biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Muscle biopsy
Description: Open muscle biopsy
Study: NCT02951689

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04492800

Intervention type: DEVICE
Group type: OTHER
Intervention: Paxman Scalp Cooling Device
Description: Cooling will consist of precooling (30 minutes); infusion cooling (will vary depending upon the length of time to infuse the chemotherapy) and post infusion cooling (90 minutes).
Study: NCT01470534

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Muscle biopsy
Description: Open muscle biopsy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Muscle biopsy
Description: Open muscle biopsy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Blood sampling
Description: Venopuncture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Venopuncture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Venopuncture

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Blood sampling
Description: Venopuncture

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00912262

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin Topical Liquid
Study: NCT04278222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Plus Toripalimab
Description: Anlotinib 12mg oral administration daily d1-d14, q3w; Toripalimab 240mg iv drop d1, q3w
Study: NCT02874417

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAST psychoeducation

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: PHET
Study: NCT03114800

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: E-Scale
Description: The E-Scale is comprised of a series of weight monitoring 'pods' and a set of software modules that facilitate data transfer and analysis.
Study: NCT03805087

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transarterial coil embolization
Description: Transarterial coil embolization of the superior rectal arteries via a transradial left arterial access.
Study: NCT02316327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine, cisplatin and bevacizumab
Description: Therapeutic
Study: NCT01639560

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: 1 mg of varenicline twice per day for 12 weeks and brief behavioral counseling

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 placebo tablet twice per day for 12 weeks and brief behavioral counseling
Study: NCT03959410

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cervical biopsy
Description: in office Cervical biopsy

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cervical biopsy
Description: in office Cervical biopsy
Study: NCT04501211

Intervention type: DRUG
Group type: OTHER
Intervention: Granisetron
Description: transdermal sancuso patch
Study: NCT03909529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin 250 MCG Oral Tablet
Description: The intervention is for study of drug drug interaction of digoxin when administered with spironolactone oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg/ 5 mL S/F Suspension
Description: The intervention is for study of drug drug interaction of digoxin when administered with spironolactone oral suspension
Study: NCT02234973

Intervention type: BEHAVIORAL
Intervention: Quality Improvement
Description: Community and Clinical Teams engaged in implementing Quality Improvement initiatives to improve diabetes prevention and management within their First Nations community and clinic.
Study: NCT03872024

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: For the first 60 patients: 3 XXL probe prototypes of the FibroScan 630 Research Model
Description: After the patient informed consent form signature and during the patient pre-operative routine hospitalization, the following examinations will be done:~* An ultrasound examination~* One examination with the FibroScan® 430 mini fitted with the XL+ probe (commercial reference)~* Three examinations with the FibroScan® 630 Expert - Research model fitted with the 3 XXL probe prototypes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: From patient 61 to patient 120: 1 XXL probe prototype of the FibroScan 630 Research Model
Description: After the patient informed consent form signature and during the patient pre-operative routine hospitalization, the following examinations will be done:~* An ultrasound examination~* One examination with the FibroScan® 430 mini fitted with the XL+ probe (commercial reference)~* One examination with the FibroScan® 630 Expert - Research model fitted with 1 adjusted XXL+ probe prototype (H+F prototype probe).
Study: NCT01470534

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02974504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: evogliptin
Description: evogliptin 5mg tablet qd + placebo tablet matching to linagliptin 5mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin
Description: linagliptin 5 mg tablet qd + placebo tablet matching to evogliptin 5mg
Study: NCT02458066

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IRS: bendiocarb
Description: carbamate insecticide

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IRS: deltamethrin
Description: Pyrethroid insecticide
Study: NCT01141816

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contrast-Enhanced Ultrasound
Description: Contrast-enhanced ultrasounds of the kidney will be performed within 7 days of routine CTs or MRIs at 3, 6, 12, 18, and 24 months post-radiofrequency ablation, with Perflutren Lipid Microsphere Injectible Suspension ('Definity') as the contrast agent.
Study: NCT04451083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOY-305
Description: Multiple-dose of FOY-305 will be administered orally at 4 times/day.
Study: NCT02387086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Study: NCT02016859

Intervention type: OTHER
Intervention: Immature Platelet Fraction

Intervention type: OTHER
Intervention: Immature Platelet Fraction

Intervention type: OTHER
Intervention: Immature Platelet Fraction
Study: NCT02387086

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gefitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Study: NCT02857504

Intervention type: DEVICE
Group type: OTHER
Intervention: double lumen tube with a hook
Description: The tube with the hook (after passing the bronchial cuff trough the vocal cords) was rotated for 180 degrees to the left and removed the stylet and when the hook passed the vocal cords, the tube was rotated for 90 degrees back to the right and push it into the bronchus. Following formula was used for the right depth (height (cm)/10 + 12 (cm)) of the tube without the hook. The tube with hook was inserted into the bronchus so that hook was placed on the carina and stopped.

Intervention type: DEVICE
Group type: OTHER
Intervention: double lumen tube without a hook
Description: Tube without the hook was inserted with the following technique: after the bronchial cuff was passed the vocal cords, the stylet was removed and the tube was rotated 90 st towards left.